Rajaii Fatemeh, McCoy Allison N, Smith Terry J
Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI 48105.
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105.
Expert Rev Ophthalmol. 2014 Jun;9(3):227-234. doi: 10.1586/17469899.2014.917960.
The pathophysiology underlying Graves' disease and its ocular manifestation, thyroid associated ophthalmopathy (TAO) is incompletely understood. Characterization of the mononuclear cells driving the disease and the cytokines they produce has led to significant advances in our understanding of TAO. This in turn has resulted in the identification of potentially attractive drug targets. For instance, development of inhibitors of specific cytokine pathways for use in other autoimmune diseases now presents an opportunity for their application in TAO. In this paper, we review the rationale for considering anti-cytokine therapy in TAO, evidence linking specific cytokines such as interleukin-6, tumor necrosis factor-α, and interleukin-17 pathways to TAO, and explore the potential for targeting of these pathways as therapy.
格雷夫斯病及其眼部表现——甲状腺相关眼病（TAO）的病理生理学尚未完全明确。对引发该疾病的单核细胞及其产生的细胞因子的特性研究，极大地推动了我们对TAO的认识。这反过来又促成了潜在有吸引力的药物靶点的发现。例如，用于其他自身免疫性疾病的特定细胞因子途径抑制剂的研发，为其在TAO中的应用带来了契机。在本文中，我们回顾了在TAO中考虑抗细胞因子治疗的理论依据、将白细胞介素-6、肿瘤坏死因子-α和白细胞介素-17等特定细胞因子途径与TAO联系起来的证据，并探讨了靶向这些途径进行治疗的潜力。
